Morgan Stanley raises Grail stock price target to $38 on cancer test potential

Published 25/06/2025, 21:58
Morgan Stanley raises Grail stock price target to $38 on cancer test potential

Investing.com - Morgan Stanley (NYSE:MS) raised its price target on Grail , Inc. (NASDAQ:GRAL) to $38.00 from $20.00 on Monday, while maintaining an Equalweight rating on the cancer detection company’s stock. The stock, which has surged over 146% year-to-date according to InvestingPro data, currently trades at $46.18.

The investment firm cited "significant long-term potential" for Grail’s Galleri multi-cancer early detection (MCED) test, which aims to detect multiple types of cancer through a single blood draw before symptoms appear.

Morgan Stanley noted that despite the promising technology, Grail faces "inherent risks associated with novel technologies from a regulatory/reimbursement pathway perspective," highlighting the challenges in gaining widespread adoption and insurance coverage.

The firm identified the upcoming National Health Service (NHS)-Galleri study readout in 2026 as the "next key catalyst" for the stock, suggesting investors should watch this clinical trial result closely.

Grail, which was founded in 2016 and went public in 2023, has positioned its Galleri test as a potential breakthrough in cancer screening, though Morgan Stanley’s Equalweight rating suggests a balanced view of the company’s near-term prospects despite the significantly higher price target.

In other recent news, GRAIL, Inc. reported its Q1 2025 earnings with a notable 19% year-over-year increase in revenue, reaching $31.8 million. The company exceeded earnings per share expectations with a result of -$3.10 compared to the anticipated -$4.26. Despite these financial achievements, GRAIL continues to face challenges with a net loss of $106.2 million and a significant cash burn. The company remains optimistic, reaffirming its full-year guidance and expecting continued growth in U.S. sales of its Galleri test. GRAIL also reported positive results from its PATHFINDER 2 study, enhancing the detection rates of its Galleri multi-cancer early detection test. Meanwhile, Canaccord Genuity raised its price target for GRAIL to $43, reflecting confidence in the company’s long-term revenue prospects. However, a report by Ningi Research raised concerns over GRAIL’s regulatory challenges and the commercial viability of its Galleri test. Additionally, GRAIL’s stockholders elected a new director and ratified Ernst & Young LLP as the company’s auditor during the recent Annual Meeting of Stockholders.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.